InvestorLens

GENB — GENERATE BIOMEDICINES INC

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying GENB?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 3 buying vs 0 selling last quarter
70
Macro Tailwind
Macro conditions are mixed for this sector
52
Why? — Evidence & Confidence ▾

Of 3 tracked investors who changed their GENB position last quarter, 3 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 52/100 in a Squeeze regime).

Supporting evidence
  • +3 tracked investors added or increased positions last quarter (Paul Tudor Jones, Izzy Englander, Cathie Wood)
  • +3 tracked investors reported holding GENB at their latest filing
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.

About GENERATE BIOMEDICINES INC (GENB)

GENERATE BIOMEDICINES INC (GENB) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Cathie Wood (ARK Investment Management), valued at $6M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in GENB

100
/100
Strong Institutional Accumulation
Added / Increased3
Reduced0
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track GENB

20
/100
Emerging Interest
3investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

GENB Ownership Composition

How GENERATE BIOMEDICINES INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Growth Funds
55% of tracked value
Institutions
3
tracked investors
Total Reported
$11.2M
combined 13F value
Sectors2
  • Growth Funds55.4%
  • Other44.6%
Growth Funds(1)
55.4%
Other(2)
44.6%

Tracked investors reporting GENB

  • Cathie WoodMar 31, 2026
    ARK Investment Management
    Shares
    498.4K
    Value
    $6.2M
    % Portfolio
    0.05%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    376.9K
    Value
    $4.7M
    % Portfolio
    0.00%
  • Paul Tudor JonesMar 31, 2026
    Tudor Investment Corp
    Shares
    23.8K
    Value
    $297.9K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold GENB?
3 tracked institutional investors disclosed a position in GENB (GENERATE BIOMEDICINES INC) in their most recent 13F filing.
Who is the largest institutional holder of GENB?
Cathie Wood, ARK Investment Management, holds the largest disclosed position in GENB, valued at $6M.
Did institutional ownership of GENB increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 fully exited GENB.
Where does this GENB ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
GENB (GENERATE BIOMEDICINES INC) — Institutional Holders & — InvestorLens